Non-steroidal antiinflammatory drugs: facts and fallacies by Wiseman, R
In 1971, Sir John Vane proposed that non-
steroidal anti-inflammatory drugs
(NSAIDs), in particular aspirin, act
through the inhibition of prostaglandin
synthesis. The ubiquitous nature of
prostaglandins and the discovery of their
physiological properties led to the deci-
phering of the mysteries of common
symptoms such as fever, pain and inflam-
mation.1,2
NSAIDs have, over the past 30 years,
become one of the most widely consumed
classes of medication in the world, with
more than 99 million prescriptions being
filled in the USA each year.3-5 Despite the
NSAIDs being seen as a highly effective
means of reducing pain and inflammation
mediated by prostaglandin release, a
major disadvantage relating to the use of
these agents has been their ability to cause
serious upper gastrointestinal complica-
tions. Reports have suggested that when
comparing NSAID users with non-users,
there is approximately a three- to fourfold
increase in risk of ulcer bleeding or perfo-
ration.4,6-9
INFLAMMATORY RESPONSE
Inflammation is a defensive and protective
response of the body to stress due to tis-
sue damage, which is usually charac-
terised by four symptoms: erythema, pain,
heat and oedema.10 Inflammation is divid-
ed into three phases: acute inflammation,
the immune response, and chronic inflam-
mation. The acute inflammatory
response is initiated by tissue injury and is
mediated by the release of autacoids.
These autacoids include histamine, sero-
tonin, prostaglandins and leukotrienes.





Normal gastrointestinal function relies on
a balance between protective mechanisms
and damaging peptic acid secretions.
Gastric surface cells produce an adherent
layer of mucus that lines the stomach.
These same cells secrete bicarbonate that
neutralises acid as it diffuses through the
mucous layer. Submucosal blood flow
also plays a key role in protecting the gas-
tric mucosa from injury by supplying oxy-
gen, nutrients and bicarbonate to the sur-
face epithelium and by removing H+ ions
that have penetrated the mucous-bicar-
bonate and epithelial barriers. Mucosal
blood flow is also essential for the devel-
opment of the ‘mucoid cap’, a complex of
mucus, fibrin and cellular debris which
provides an alkaline environment for the
injured epithelium so that re-epithelialisa-
tion can occur.
Virtually all cells of the gastrointestinal
tract are capable of synthesising
prostaglandins. Endogenous
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This article serves to review NSAIDs, their 
mechanism of action and adverse effects, as well
as to establish the therapeutic position of the
new-generation NSAIDs, the COX II selective
i n h i b i t o r s .
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mechanisms of mucosal defence.
They inhibit acid secretion and
increase mucus secretion, bicar-
bonate secretion and mucosal
blood flow. Furthermore,
prostaglandins stabilise mucosal
mast cells and prevent disruption





piroxicam, exert their anti-inflam-
matory action by reversibly or irre-
versibly (in the case of aspirin)
inhibiting the cyclo-oxygenase
(COX) enzyme, responsible for
converting arachidonic acid into
the va rious forms of prostaglandins,
in a non-selective manner.5,13-16 Fig.
1 is a diagrammatic representation
of the prostaglandin pathway.
Our understanding of the mode of
action of the NSAIDs as inhibitors
of COX has been significantly
expanded by the description of dif-
ferent forms of this enzyme. The
accumulated evidence suggests that
there are at least two isoforms of
the COX enzyme, namely COX I
and COX II isoenzymes. COX I is
a constitutive form of the enzyme
which is inhibited, at least to some
degree, by all the commercially
available NSAIDs. COX I is
thought to have an integral role in
maintaining the integrity of the
gastric and duodenal mucosa, reg-
ulation of renal blood flow and
platelet aggregation.16-18 The sec-
ond isoform of the COX enzyme,
COX II, is an inducible enzyme
which, under normal circum-
stances, is undetectable.The
expression of COX II is markedly
increased during states of inflam-
mation.As more has been learned
about NSAIDs, the importance of
the inhibition of prostaglandin syn-
thesis, in particular the COX II
isoenzyme, as a major mode of
action is highlighted.5,11
By inhibiting the COX enzyme in a
non-selective manner, the inflam-
matory process is markedly
decreased; however, the regulatory
physiological functions, which are
also prostaglandin mediated, are
inhibited by the same mechanism
of action.
NSAID TOXICITY
Schoen and Vender20 were the first
to suggest that the mechanism
whereby NSAIDs damage the gas-
trointestinal mucosa was as a result
of a ‘dual insult’ mechanism. This
mechanism of insult can be divided
into two areas:
• local injury, which is pH-depen-
dent and varies greatly among
the different NSAIDs
• systemic injury, a process that is
less drug-specific and does not
depend on direct mucosal con-
tact (Fig. 2).4,11
Local injury
Most NSAIDs are weakly acidic,
lipid-soluble compounds that dif-
fuse across cell membranes into
gastric surface cells. Once inside
these gastric surface cells, they are
no longer lipid-soluble and there-
fore are unable to diffuse back into
the aqueous acid. Damage to the
surface cells breaks down the nor-
mal protective mechanisms and
allows diffusion of acid into the
submucosa, resulting in mucosal
injury.4,11
Systemic injury
Following Vane’s hypothesis (1971)
it is now generally accepted that
NSAIDs inhibit the enzyme cyclo-
oxygenase that transforms arachi-
donic acid to prostaglandins.14,15
As has been discussed, normal gas-
trointestinal function relies on a
balance between the protective
mechanisms of prostaglandins ver-
sus the damaging effects of peptic
acid secretions. Considering that
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TxA2 = thromboxane A2; PGI2 = prostaglandin I2; PGE2 = prostaglandin E2.
Fig. 1. Diagrammatic representation of the prostaglandin pathway.19
NSAIDs are reversible inhibitors of
cyclo-oxygenase, the key enzyme in
prostaglandin formation, it follows
that the impairment of these pro-
tective functions will allow chronic
gastrointestinal injury to occur.4
The mechanisms by which
NSAIDs induce mucosal injury
are:12
• increased gastric acid secretion
• decreased duodenal bicarbonate
output
• decreased gastric mucosal blood
flow
• effect on mucous synthesis secre-
tion via:
• inhibited mucous synthesis
• reduced incorporation of pre-
cursors into mucous glycopro-
tein
• altered thickness of the mucous
layer.
Risk factors for NSAID
toxicity
Previous reports have identified
five variables that pose as indepen-
dent risk factors that predispose
NSAID users to gastrointestinal
complications:4,8,21,22
• increasing age (over 60 years)
• previous history of ulcer and
ulcer complications
• concomitant use of cortico-
steroids and other ulcerogenic
substances
• use of high doses of NSAIDs
• concomitant use of anticoagulant
therapy.
The elderly are a population group
that appear to be increasingly vul-
nerable to the adverse effects of the
NSAID mechanism of action.
Apart from a greater need for gen-
eralised pain relief , this vulnerabili-
ty is as a result of a combination of
various physiological and pharma-
cokinetic factors.
Increasing age sees a reduction in
the ability to biotransform and
inactivate hepatically metabolised
agents. This is largely as a result
of a decrease in liver mass and a 
40 - 45% reduction in hepatic
blood flow.16,23,24 The elderly also
display markedly reduced renal
function, which is often age-relat-
ed.25 Accordingly, the decreased
elimination of renally excreted
drugs, including NSAIDs, will
result in an elevated half-life and
therefore greater susceptibility to
the drug’s side-effect profile.26
COX II INHIBITORS
Gastrointestinal effects
With the ever-increasing incidence
of gastrointestinal adverse effects, it
has become necessary to investi-
gate options that would provide
effective treatment for inflammato-
ry type situations, while ensuring
the uncompromised effectiveness
of the physiological COX I isoen-
zyme.The COX II selective
inhibitors have emerged as an
important option in the treatment
of inflammatory diseases, including
rheumatoid arthritis. Reports have
suggested that rofecoxib and cele-
coxib, the two COX II selective
inhibitors that are currently avail-
able, have shown comparable effi-
cacy to that of the conventional
NSAIDs and should, when used in
the correct target population, i.e.
those with NSAID-attributable
risk, lead to improved out-
comes.17,27,28 Theoretically, COX II
inhibitors should decrease inflam-
mation by inhibiting the formation
of prostaglandins responsible for
causing inflammation, while leav-
ing the COX I pathway intact, the
pathway responsible for regulating
the body’s normal physiological
function.29
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The elderly are a
population group
that appear to be
increasingly vulnera -
ble to the adverse
effects of the NSAID
mechanism of






   
    
 
   
 








     
  





Fig. 2. A diagrammatic representation of the dual insult mechanism of NSAID-
induced gastric damage involving systemic and local effects.11
The key issue regarding this new
COX II technology is that the
COX II inhibitors are only highly
selective inhibitors of the COX II
isoenzyme rather than being specific
inhibitors.29 Although this may
appear to be a pedantic turn of
phrase, it has significant therapeu-
tic implications. The issue that pre-
sents itself in this instance is that
being highly selective rather than
specific inhibitors of COX II
implies that despite having a
greater affinity for COX II, there
will still be some inhibition of the
COX I isoenzyme. Studies have
shown that despite maximum
doses of comparator drugs being
used (diclofenac 150 mg and
ibuprofen 2 400 mg) the incidence
of total serious adverse events (as
defined by the US Food and Drug
Administration) was similar in
both groups (celecoxib 4.3%,
NSAIDs 4.2%), as were deaths.30
Renal effects
Promotional material pertaining to
the renal safety of the COX II
selective inhibitors has also met
with some controversy. Current
expert opinion is that COX II is
constitutively expressed in renal
tissues of all species.Therefore, this
isoenzyme may be intimately
involved in prostaglandin-depen-
dent renal homeostatic processes.
This assertion is borne out by
recent clinical studies showing that
the COX II inhibitors, rofecoxib
and celecoxib, cause qualitative
changes in urinary prostaglandin
excretion, glomerular filtration rate
and sodium retention.These
reports have gone so far as to sug-
gest that the renal effects of the
COX II inhibitors may even be
similar to those described for the
non-selective NSAIDs and there-
fore should be used with caution in
patients with fluid retention, heart
failure and hypertension.31,32
THERAPEUTIC OPTIONS
Amid the hype of the potential
benefits of the COX II inhibitors
as well as the contradictory reports
surrounding their specificity and
safety profile, the intention of this
review is not to overlook the signif-
icant advances that have been
made with respect to COX II tech-
nology. It is true that the COX II
inhibitors have a greater affinity
towards the COX II isoenzyme,
but it should be remembered that,
at this point, there will always be a
certain degree of COX I inhibition.
This, as well as a few basic princi-
ples when prescribing NSAIDs,
should be remembered:30
• Avoid NSAIDs wherever possi-
ble. Most cases of osteoarthritis
require pain relief rather than
NSAID therapy. Simple anal-
gesics such as paracetamol with
or without codeine should be
tried. Low-dose amitriptyline
can often be safely added to
improve pain control.
• Use the lowest effective dose of
the NSAID for the shortest pos-
sible period in cases not con-
trolled by the above.
• For first-line treatment, use
NSAIDs with a lower incidence
of gastrointestinal complications,
namely ibuprofen and diclofenac.
Where the use of an NSAID seems
warranted, but where it is associat-
ed with unacceptable adverse
effects or the risk of NSAID-asso-
ciated complications is excessively
high, the following should be con-
sidered:
• In the case of non-ulcer dyspep-
sia, therapy should be changed to
an alternative NSAID as there
may be a large inter-patient vari-
ability with regard to differences
in tolerability of the various
NSAIDs available. Failing this, a
generic H2-antagonist should be
added for adequate symptom
control.
• In patients with predisposing risk
factors, where the risk of upper
gastrointestinal complications is
thought to be excessive and
NSAIDs are required for ade-
quate pain relief, a proton pump
inhibitor, the prostaglandin ana-
logue, misoprostol, or a low dose
of a COX II inhibitor should be
considered. If it is decided to
introduce either a proton pump
inhibitor or misoprostol, the
cheapest effective NSAID should
be chosen as the cost of prescrib-
ing a COX II inhibitor with a 
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It is true that the
C O X II inhibitors
have a greater affini -
ty towards the COX
II isoenzyme, but it
should be remem -
bered that, at this
point, there will
always be a certain
degree of COX I I






NSAIDs have been available for
more than 30 years — three
decades that have yielded signifi-
cant therapeutic benefit for some,
while others have manifested of
severe adverse reactions. This
uncompromising side-effect profile
has resulted in the NSAID class, as
a whole, being shrouded in contro-
versy. The advent of the ‘super
aspirins’, otherwise known as the
highly selective COX II inhibitors,
has certainly not escaped this
tumultuous journey. Even though
the COX II inhibitors have shown
promise of true therapeutic
advancement, it is evident that
these agents are not without their
shortcomings. As time has pro-
gressed since the launch of these
agents onto the global pharmaceu-
tical market, it has become increas-
ingly evident that this sub-class of
NSAIDs should be prescribed with
the same caution as c o nve n t i o n a l
N S A I D s. F u rt h e rm o r e , in the inter-
est of cost containment, it may be
considered prudent to adopt a
more conservative approach when
considering one’s therapeutic
options in treating inflammatory
disorders.
References available on request.
MAIN TOPIC
84 C M E F e b ru a r y  2 0 0 3   Vo l . 2 1   N o . 2
IN A NUTSHELL
Inflammation is a defensive and pro-
tective response characterised by ery-
thema, pain, heat and oedema.
The acute inflammatory response is
initiated by tissue injury and mediated
by autacoids, namely histamine, sero-
tonin, pro staglandins and leukotrienes.
Normal gast ro i n t e stinal function
depends on a balance between pro-
tective mechanisms and acid secre-
t i o n s .
NS A IDs upset this balance by inhibit-
ing the COX enzyme ( I and II) which
c o n v e rt arachidonic acid into
p ro sta g l a n d i n s .
NS A IDs which selectively inhibit the
COX II enzyme have emerged as
effective therapy for inflammatory dis-
eases, while leaving the COX I path-
way inta c t .
As they are selective rather than spe-
cific inhibitors of COX II, some inhibi-
tion of the COX I enzyme still occurs.
NS A IDs, should always be used with
caution, especially in patients at risk
for gast ro i n t e stinal complications, fluid
retention, heart failure and hypert e n-
sion. 
SINGLE SUTURE
Blood pressure and cognitive impairment in heart failure patients
In an Italian study published in Neurology (2001; 57: 1986-1992), cognitive impairment was found signifi-
cantly more frequently among patients with heart failure than among those without heart failure (26% v.
19%). In analyses adjusted for several confounding variables, cognitive dysfunction was associated with
lower systolic blood pressure (BP) among heart failure patients: systolic BP lower than 130 mmHg was
found in 46% of heart failure patients with cognitive impairment and in 27% of those without impairment
— a significant difference. Among patients without heart failure, there was no correlation between BP and
cognitive dysfunction.
Allan S Brett, MD, writing in Journal Watch (8 January  2002), comments, ‘Undoubtedly there are other
confounding variables that were not accounted for in this study, and causal links between heart failure, cog-
nition, and BP remain unclear. Because hypotensive drugs are a mainstay of heart failure therapy, we will
face a dilemma if additional research shows that active lowering of systolic BP to below 130 mmHg increas-
es risk for cognitive dysfunction among heart failure patients.’
